UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):  February 8, 2005

 

ARENA PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in Charter)

 

Delaware

 

000-31161

 

23-2908305

(State or Other Jurisdiction
of Incorporation)

 

(Commission File Number)

 

(I.R.S. Employer
Identification No.)

 

6166 Nancy Ridge Drive, San Diego, California 92121

(Address of Principal Executive Offices)   (Zip Code)

 

(858) 453-7200

(Registrant’s telephone number, including area code)

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 


 

Item 8.01                                             Other Events.

 

On February 8, 2005, Arena Pharmaceuticals, Inc. announced that the underwriters have exercised in full their over-allotment option to purchase 1,125,000 shares of common stock in connection with its follow-on stock offering that priced on February 1, 2005.  A copy of Arena’s press release dated February 8, 2005, relating to the underwriters’ exercise of the over-allotment option is attached hereto as Exhibit 99.1.

 

Item 9.01                                             Financial Statements and Exhibits.

 

(c) Exhibits.

 

Exhibit
Number

 

Description

 

 

 

99.1

 

Press Release dated February 8, 2005

 

2


 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: February 8, 2005

Arena Pharmaceuticals, Inc.,

 

a Delaware corporation

 

 

 

 

 

By:

/s/ Jack Lief

 

 

 

Jack Lief,

 

 

President and Chief Executive Officer

 

3


 

Exhibit Index

 

Exhibit No.

 

Description

 

 

 

99.1

 

Press Release dated February 8, 2005

 

4